10-K: 2seventy bio, Inc. Announces 2024 Results and Provides Business Update Amidst Proposed BMS Acquisition

2seventy bio, Inc. reports its 2024 financial results, highlighting Abecma's commercial performance and strategic realignment, while awaiting a proposed acquisition by Bristol-Myers Squibb (BMS).

Summary

• 2seventy bio, Inc., a cell therapy company, has released its Form 10-K filing for the fiscal year ended December 31, 2024.
• The company is focused on the commercialization and development of Abecma, a CAR T-cell therapy for multiple myeloma, in partnership with BMS.
• A strategic realignment was undertaken in January 2024 to concentrate on Abecma, leading to the sale of other oncology and autoimmune programs to Regeneron and the megaTAL platform to Novo Nordisk.
• On March 10, 2025, 2seventy bio entered into a merger agreement with BMS, pending tender offer and regulatory approvals, which would result in 2seventy bio becoming a wholly-owned subsidiary of BMS.
• The company's net losses for 2024 were $57.2 million, compared to $217.6 million in 2023.
• Revenue from Abecma sales in the U.S. in 2024 totaled $242 million, shared equally with BMS.
• The FDA approved Abecma for relapsed or refractory multiple myeloma after two or more prior lines of therapy on April 4, 2024.
• Enrollment in the Phase 3 KarMMa-9 study was discontinued in September 2024.
• As of December 31, 2024, 2seventy bio held $183.6 million in cash, cash equivalents, and marketable securities.
• The company anticipates these funds will be sufficient to support planned operations for at least the next twelve months.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is being acquired, which is generally positive, the financial results show a loss and there are risks associated with the acquisition.

Positives

• FDA approval of Abecma for use after two or more lines of therapy.
• Strategic realignment to focus on Abecma, potentially streamlining operations.
• Proposed acquisition by BMS, offering stockholders $5.00 per share.
• Decrease in net losses from $217.6 million in 2023 to $57.2 million in 2024.
• Significant cash, cash equivalents, and marketable securities on hand ($183.6 million as of December 31, 2024).

Negatives

• The company has incurred significant losses and anticipates continued losses.
• The proposed acquisition by BMS is subject to conditions and may not be completed.
• Dependence on BMS for the commercialization, manufacture, and development of Abecma.
• Potential product liability claims and adverse events associated with Abecma.
• Competition in the multiple myeloma market from other therapies.

Risks

• Failure to complete the proposed acquisition by BMS could negatively impact the stock price.
• The company may need to raise additional funding, which may not be available on acceptable terms.
• Strategic realignment may not be as successful as anticipated.
• Serious adverse events associated with Abecma may impact commercial sales.
• Reliance on third parties for manufacturing and testing may lead to unsatisfactory performance.

Future Outlook

The company expects its cash, cash equivalents and marketable securities will be sufficient to fund current planned operations for at least the next twelve months.

Industry Context

The document provides insight into the competitive landscape of multiple myeloma treatment, including the development of autologous and allogeneic CAR-T cell therapies, bispecific T cell engagers, and antibody-drug conjugates.

Comparison to Industry Standards

• The document mentions Carvykti (ciltacabtagene autoleucel) marketed by Janssen in collaboration with Legend Biotech, which is a direct competitor to Abecma.
• It also references Tecvayli (teclistamab) developed by Janssen, Elrexfio (elranatamab) by Pfizer, and linvoseltamab by Regeneron as bispecific antibody therapies competing in the same market.
• The document notes the withdrawal of Blenrep (belantamab mafodotin) by GSK, highlighting the challenges and risks associated with developing and maintaining approval for BCMA-targeting therapies.

Stakeholder Impact

• Shareholders: Potential for a return on investment through the proposed acquisition by BMS.
• Employees: Workforce reductions and transitions to Regeneron and Novo Nordisk.
• Patients: Continued access to Abecma for multiple myeloma treatment.
• Collaboration partners: Ongoing collaboration with BMS for Abecma development and commercialization.

Next Steps

• Complete the proposed acquisition by BMS.
• Continue to support the commercial growth of Abecma.
• Manage the transition of divested assets to Regeneron and Novo Nordisk.

Key Dates

Keywords

Abecma, Multiple Myeloma, BMS, Cell Therapy, Regeneron, Novo Nordisk, Acquisition, Financial Results, Ide-cel, KarMMa